(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/212536 A1

(51) International Patent Classification:
C12N 50/0783 (2006.01) *A61P 35/00* (2006.01)
A61K 40/31 (2025.01) *A61K 35/17* (2025.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2025/022371

(22) International Filing Date:
31 March 2025 (31.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/572,671 01 April 2024 (01.04.2024) US

(71) Applicant: **MOONLIGHT BIO, INC.** [US/US]; 1616 Eastlake Ave. E., Alexandria LaunchLabs Suite 208, Seattle, Washington 98102 (US).

(72) Inventors: **ALBERSHARDT, Ting-Lan**; c/o Moonlight Bio, Inc., 1616 Eastlake Ave. E., Alexandria LaunchLabs Suite 208, Seattle, Washington 98102 (US). **DANIELS, Jay Carroll**; c/o Moonlight Bio, Inc., 1616 Eastlake Ave. E., Alexandria LaunchLabs Suite 208, Seattle, Washington 98102 (US). **GARCIA, Julie Marie**; c/o Moonlight Bio, Inc., 1616 Eastlake Ave. E., Alexandria LaunchLabs Suite 208, Seattle, Washington 98102 (US). **JARJOUR, Jordan**; c/o Moonlight Bio, Inc., 1616 Eastlake Ave. E., Alexandria LaunchLabs Suite 208, Seattle, Washington 98102 (US).

(74) Agent: **CHRISTIANSEN, William T.** et al.; Cooley LLP, ATTN: IP Docketing Department, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: THERAPEUTIC ANTIBODY EPITOPE-TAGGED CAR T CELLS FOR ENHANCED CONTROL AND SAFETY

FIG. 1C



(57) Abstract: The present disclosure relates generally to compositions and methods for improving the safety of adoptive immune cell therapy, including the use of a depletion tag (*e.g.*, an epitope or a mimotope) that is capable of being bound by another molecule (*e.g.*, an antibody) to facilitate the depletion of the engineered immune cells. One class of depletion tags disclosed herein contain an epitope or mimotope derived from a biomarker of a hematologic cancer (*e.g.*, CCR4). A second class of depletion tags disclosed herein contain an epitope or mimotope derived from the same antigen that the engineered receptor binds to (*e.g.*, a DLL3 derived depletion tag for engineered immune cells that bind to DLL3).

WO 2025/212536 A1